ClinicalTrials.gg
RecruitingNCT04028687Updated Oct 13, 2026

MDR - PMCF Study for Taperloc Complete Stems

An observational study in Hip Arthritis, Hip Disease and Hip Fractures, sponsored by Zimmer Biomet. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Zimmer Biomet · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
820
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Hip Fractures by Zimmer Biomet — 5 open to participants now, 8 under way, none of them phase 3. Hip Fractures · Zimmer Biomet.

Planned enrollment
Largest of 11
820 · median 149
Started
2020
with 2 others
Observational
11 of 16
3 open now
Registered
6th of 16
by date

Among the 16 studies in Hip Fractures by Zimmer Biomet, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2020, is one of 11 observational ones, and was the 6th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

5 of the 16 studies in Hip Fractures by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hip Fractures by Zimmer Biomet, or all of them as a file.
02

Study summary

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.

Read the detailed description

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.

The primary objective is to confirm safety of the study products. This will be assessed by recording the incidence and frequency of revisions, complications, and adverse events. Relationship of the events to either implant or instrumentation should be specified.

The secondary objective is the assessment of performance and clinical benefits by analyzing recorded patient-reported clinical outcomes measures (PROMs).

*The most recent available data will be used. If any of the listed time points are not available, data will be used from last available time point and follow-up will move forward at the closest available time point

03

Conditions studied

  • Hip Arthritis
  • Hip Disease
  • Hip Fractures
  • Hip Injuries
  • Hip Pain Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A consecutive series of patients implanted with the Taperloc Complete Stems in primary or revision total hip arthroplasty according to the approved indications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years of age or older and skeletally mature
  • Patient must be willing and able to sign IRB approved
  • Patient must have undergone primary or revision hip arthroplasty with the -Taperloc Complete stem according to a cleared indication, which includes the following:
  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
  • Rheumatoid arthritis
  • Correction of functional deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques

Exclusion criteria

Exclusion Criteria:

  • Off-label use
  • Infection
  • Sepsis
  • Osteomyelitis
  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy, or neuromuscular disease
  • Patient is known to be pregnant or nursing
  • Patient is a prisoner
  • Patient is a known alcohol or drug abuser
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
820 participants (estimated)
Patient registry
No

Groups and cohorts

  • Taperloc Complete Stems

    Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.

    Device: Taperloc Complete Stem

Interventions

  • DeviceTaperloc Complete Stem

    Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.

06

What researchers measure

Primary outcomes

  1. Device Safety assessed through the frequency and incidence of revisions, complications and Adverse Events.

    The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to either implant or instrumentation should be specified.

    Time frame: Out to 10 Years

Secondary outcomes

  1. Device Performance and Benefits evaluated through the Harris Hip Score

    The HHS is divided into 4 sub-categories; pain (44 points), function (47 points), range of motion (5 points), and absence of deformity (4 points). Patients select a discrete set of answers which correspond to predefined point allocations based on the category. To obtain a final score, these values are summed.

    Time frame: Out to 10 Years

  2. Device Performance and Benefits evaluated through the Oxford Hip Score

    The OHS is a patient-completed, 12-question evaluation. Each item is scored from 1 to 5, with 1 representing best outcome/least symptoms and 5 representing worst outcome/most symptoms.

    Time frame: Out to 10 Years

07

Study locations

1 of 3 sites recruiting
  • Orthopaedic Institute of Henderson
    Henderson, Nevada 89052, United States
    Withdrawn

    Not enrolling at this site.

  • Texas Health Physicians Group
    Plano, Texas 75243, United States
    Recruiting
  • Proliance Orthopaedics and Sports Medicine
    Bellevue, Washington 98004, United States
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Feb 2032, 143 months after the start.

Of 124 observational studies under Hip Fractures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 143 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2019
First posted
Jul 23, 2019
StartActual
Feb 13, 2020
Primary completionEst.
Feb 12, 2032
CompletionEst.
Feb 12, 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04028687
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Feb 13, 2020
Primary completion
Feb 12, 2032 (estimated)
Completion
Feb 12, 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Megan McKinnie
Contact
megan.mckinnie@zimmerbiomet.com
+1 (919) 381-7091
Lynsey Boyle
Contact
Lynsey.Boyle@zimmerbiomet.com
+1 (412) 552-7111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion